Telix Pharmaceuticals Limited (TLPPF)
- Previous Close
19.25 - Open
19.25 - Bid 18.00 x 40000
- Ask 19.10 x 40000
- Day's Range
19.25 - 19.25 - 52 Week Range
8.90 - 24.85 - Volume
1,000 - Avg. Volume
4,284 - Market Cap (intraday)
6.443B - Beta (5Y Monthly) 2.49
- PE Ratio (TTM)
213.89 - EPS (TTM)
0.09 - Earnings Date Feb 20, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.
telixpharma.comRecent News: TLPPF
View More
Performance Overview: TLPPF
Trailing total returns as of 4/28/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TLPPF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TLPPF
View MoreValuation Measures
Market Cap
6.08B
Enterprise Value
6.00B
Trailing P/E
209.18
Forward P/E
68.97
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
13.33
Price/Book (mrq)
17.82
Enterprise Value/Revenue
12.04
Enterprise Value/EBITDA
101.90
Financial Highlights
Profitability and Income Statement
Profit Margin
6.37%
Return on Assets (ttm)
5.32%
Return on Equity (ttm)
13.92%
Revenue (ttm)
783.21M
Net Income Avi to Common (ttm)
49.92M
Diluted EPS (ttm)
0.09
Balance Sheet and Cash Flow
Total Cash (mrq)
710.35M
Total Debt/Equity (mrq)
102.33%
Levered Free Cash Flow (ttm)
72.81M